Deirdre A Lane

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5079025/deirdre-a-lane-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28,086 164 308 74 h-index g-index citations papers 360 35,363 7.29 5.5 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
308	Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-8	2.9	
307	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry <i>European Journal of Clinical Investigation</i> , 2022 , e13773	4.6	1
306	Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke <i>Stroke</i> , 2022 , STROKEAHA121037316	6.7	2
305	Risk of Cerebrovascular Events in Intracerebral Hemorrhage Survivors With Atrial Fibrillation: A Nationwide Cohort Study <i>Stroke</i> , 2022 , 101161STROKEAHA121038331	6.7	1
304	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021 , 19, 256	11.4	4
303	Prospective randomised trial examining the impact of an educational intervention versus usual care on anticoagulation therapy control based on an SAMe-TTR score-guided strategy in anticoagulant-naWe Thai patients with atrial fibrillation (TREATS-AF): a study protocol. <i>BMJ Open</i> ,	3	1
302	2021 , 11, e051987 Patient Satisfaction: A Key Component in Increasing Treatment Adherence and Persistence. Thrombosis and Haemostasis, 2021 , 121, 255-257	7	1
301	Prevalence of atrial fibrillation and outcomes in older long-term care residents: a systematic review. <i>Age and Ageing</i> , 2021 , 50, 744-757	3	2
300	Utilization and perception of same-day discharge in electrophysiological procedures and device implantations: an EHRA survey. <i>Europace</i> , 2021 , 23, 149-156	3.9	5
299	Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology. <i>European Journal of Internal Medicine</i> , 2021 , 86, 1-11	3.9	12
298	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021 , 23, 1612-1676	3.9	99
297	Mobile Apps to Improve Medication Adherence in Cardiovascular Disease: Systematic Review and Meta-analysis. <i>Journal of Medical Internet Research</i> , 2021 , 23, e24190	7.6	12
296	Associations between COVID-19 and 30-day thromboembolic events and mortality in people with dementia receiving antipsychotic medications. <i>Pharmacological Research</i> , 2021 , 167, 105534	10.2	1
295	Gull ESC 2020 sobre el diagnilico y tratamiento de la fibrilacifi auricular, desarrollada en colaboracifi de la European Association of Cardio-Thoracic Surgery (EACTS). <i>Revista Espanola De Cardiologia</i> , 2021 , 74, 437.e1-437.e116	1.5	3
294	The Atrial Fibrillation Better Care pathway for managing atrial fibrillation: a review. <i>Europace</i> , 2021 , 23, 1511-1527	3.9	4
293	Exercise-Based Cardiac Rehabilitation and All-Cause Mortality Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2021 , 10, e020804	6	4
292	The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, f81-f83	6.4	4

291	Optimization of atrial fibrillation care: management strategies and quality measures. <i>European Heart Journal Quality of Care & Dutcomes</i> , 2021, 7, 121-133	4.6	0
2 90	Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults 150 years with COVID-19. <i>Journal of Arrhythmia</i> , 2021 , 37, 231-237	1.5	11
289	End-Stage renal disease and 30-day mortality for adults with and without COVID-19. <i>European Journal of Internal Medicine</i> , 2021 , 83, 93-95	3.9	1
288	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC)	9.5	1676
287	Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace, 2021, 23, 494-49	9 5 .9	23
286	Higher Mortality of Ischaemic Stroke Patients Hospitalized with COVID-19 Compared to Historical Controls. <i>Cerebrovascular Diseases</i> , 2021 , 50, 326-331	3.2	7
285	2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia	1.5	3
284	2021 ISHNE/ HRS/ EHRA/ APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia	1.5	10
283	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. <i>Europace</i> , 2021 , 23, 806-814	3.9	О
282	2021 ISHNE/HRS/EHRA/APHRS Expert Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm	6.4	16
281	2021 ISHNE/HRS/EHRA/APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals: From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia	2	2
280	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	4
279	Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-19 patients. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13679	4.6	16
278	Mobile health solutions for atrial fibrillation detection and management: a systematic review. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	4
277	Association of Exercise-Based Cardiac Rehabilitation with Progression of Paroxysmal to Sustained Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
276	2021 ISHNE / HRS / EHRA / APHRS Collaborative Statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm ProfessionalsFrom the International Society for Holter and Noninvasive Electrocardiology / Heart Rhythm Society / European Heart Rhythm	2.3	1
275	Modelling of longitudinal data to predict cardiovascular disease risk: a methodological review <i>BMC Medical Research Methodology</i> , 2021 , 21, 283	4.7	О
274	The Effects of Implementing a Mobile Health-Technology Supported Pathway on Atrial Fibrillation-Related Adverse Events Among Patients With Multimorbidity: The mAFA-II Randomized Clinical Trial <i>JAMA Network Open</i> , 2021 , 4, e2140071	10.4	4

273	Mobile health technology facilitates population screening and integrated care management in patients with atrial fibrillation. <i>European Heart Journal</i> , 2020 , 41, 1617-1619	9.5	2	
272	CliniciansPviews and experiences of prescribing oral anticoagulants for stroke prevention in atrial fibrillation: A qualitative meta-synthesis. <i>PLoS ONE</i> , 2020 , 15, e0232484	3.7	6	
271	Letter by Guo et al Regarding Article, "SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation". <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020 , 13, e006635	5.8		
270	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020 , 9, e014932	6	36	
269	Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. <i>Thrombosis Research</i> , 2020 , 192, 12-20	8.2	6	
268	The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. <i>Internal and Emergency Medicine</i> , 2020 , 15, 1183-1192	3.7	16	
267	The Compelling Issue of Nonvitamin K Antagonist Oral Anticoagulant Adherence in Atrial Fibrillation Patients: A Systematic Need for New Strategies. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 36	9 ⁷ 371	7	
266	Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies. <i>Frontiers in Medicine</i> , 2020 , 7, 54	4.9	9	
265	Peri-procedural management, implantation feasibility, and short-term outcomes in patients undergoing implantation of leadless pacemakers: European Snapshot Survey. <i>Europace</i> , 2020 , 22, 833-8	338 ⁹	6	
264	Mobile Health Technology to Improve Care for Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1523-1534	15.1	99	
263	Lifestyle and risk factor modification for reduction of atrial fibrillation: We could do more. <i>Trends in Cardiovascular Medicine</i> , 2020 , 30, 387-388	6.9	0	
262	Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 788-790	15.4	3	
261	Etiologic Workup in Cases of Cryptogenic Stroke: A Systematic Review of International Clinical Practice Guidelines. <i>Stroke</i> , 2020 , 51, 1419-1427	6.7	13	
260	Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial. <i>American Journal of Medicine</i> , 2020 , 133, 1195-1202.e2	2.4	44	
259	Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. <i>European Heart Journal</i> , 2020 , 41, 1132-1140	9.5	16	
258	Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. <i>European Heart Journal Supplements</i> , 2020 , 22, O14-O27	1.5	5	
257	Atrial fibrillation in low- and middle-income countries: a narrative review. <i>European Heart Journal Supplements</i> , 2020 , 22, O61-O77	1.5	3	
256	Validation of the modified Microlife blood pressure monitor in patients with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2020 , 109, 802-809	6.1	О	

(2019-2020)

255	Real-worldPobservational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace,	3.9	14
254	2020 , 22, 831-832 Lipid levels, atrial fibrillation and the impact of age: Results from the LIPIDOGRAM2015 study. <i>Atherosclerosis</i> , 2020 , 312, 16-22	3.1	8
253	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , 2020 , 22, I1-I12	1.5	2
252	Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. <i>Europace</i> , 2020 ,	3.9	11
251	Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. <i>PLoS Medicine</i> , 2020 , 17, e1003321	11.6	179
250	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 61-71	4	12
249	Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 27-35	7	18
248	Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2365-2375	15.1	142
247	Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 294-307	7	31
246	Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 612-619	15.1	67
245	Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: The mAFA (mAF-App) II randomised trial. <i>International Journal of Clinical Practice</i> , 2019 , 73, e13352	2.9	36
244	The Liverpool Centre for Cardiovascular Science. European Heart Journal, 2019, 40, 957-958	9.5	
243	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019 , 21, 1116-1125	3.9	8
242	Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 619-633	3.8	35
241	Integrated care for the management of atrial fibrillation: what are the key components and important outcomes?. <i>Europace</i> , 2019 , 21, 1759-1761	3.9	2
240	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , 2019 , 83, 2434-2442	2.9	4
239	Psychotropic drug use following venous thromboembolism versus diabetes mellitus in adolescence or young adulthood: a Danish nationwide cohort study. <i>BMJ Open</i> , 2019 , 9, e026159	3	2
238	Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa	3.9	30

237	Etiologic workup in cases of cryptogenic stroke: protocol for a systematic review and comparison of international clinical practice guidelines. <i>Systematic Reviews</i> , 2019 , 8, 331	3	2
236	Cognitive Behavioral Therapy for Depression, Anxiety, and Stress in Caregivers of Dementia Patients: A Systematic Review and Meta-Analysis. <i>Gerontologist, The</i> , 2019 , 59, e343-e362	5	27
235	Epidemiology of atrial fibrillation. International Journal of Clinical Practice, 2018, 72, e13070	2.9	80
234	Use of leadless pacemakers in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2018 , 20, 555-559	3.9	22
233	Incident Heart Failure in Patients With Rheumatoid Arthritis: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	27
232	Individual depressive symptoms and all-cause mortality In 6673 patients with myocardial infarction: Heterogeneity across age and sex subgroups. <i>Journal of Affective Disorders</i> , 2018 , 228, 178-185	6.6	6
231	Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1404-1406	9.5	8
230	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018 , 20, 395-407	3.9	66
229	Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. <i>Clinical Cardiology</i> , 2018 , 41, 855-861	3.3	21
228	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Heart Rhythm</i> , 2018 , 15, e37-e60	6.7	16
227	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. <i>Europace</i> , 2018 , 20, 1399-1421	3.9	41
226	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. <i>Europace</i> , 2018 , 20, 1231-1242	3.9	148
225	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>European Heart Journal</i> , 2018 , 39, 1330-	9393	1094
224	Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. Journal of Internal Medicine, 2018 , 283, 282-292	10.8	16
223	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoanericana de Estimulacili Cardiaca y Electrofisiologia	9.5	24
222	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: What is the best practice?. <i>Journal of Arrhythmia</i> , 2018 , 34, 99-123	1.5	7
221	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. <i>American Journal of Medicine</i> , 2018 , 131, 1359-1366	5.e6	71
220	Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2018 , 154, 1121-1201	5.3	502

219	Guideline-adherent secondary prevention post-acute coronary syndromes: the importance of patient uptake and persistence. <i>European Heart Journal</i> , 2018 , 39, 2365-2367	9.5	5
218	Use of the SAMe-TTR score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review. <i>Heart Rhythm</i> , 2018 , 15, 615-623	6.7	17
217	Qualitative exploration of the effect of a television soap opera storyline on women with experience of postpartum psychosis. <i>BJPsych Open</i> , 2018 , 4, 75-82	5	2
216	PatientsPPerceptions of Atrial Fibrillation, Stroke Risk, and Oral Anticoagulation Treatment: An International Survey. <i>TH Open</i> , 2018 , 2, e233-e241	2.7	9
215	Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. <i>Psychosomatic Medicine</i> , 2018 , 80, 742-	753	64
214	Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: A comparison between EORP-AF pilot and EHS-AF registries. <i>European Journal of Internal Medicine</i> , 2018 , 55, 28-34	3.9	37
213	Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care. Journal of the American Heart Association, 2017 , 6,	6	127
212	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , 2017 , 18, 199-203	8.8	11
211	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <i>The Cochrane Library</i> , 2017 , 4, CD008600	5.2	31
210	PatientsPexperiences of atrial fibrillation and non-vitamin K antagonist oral anticoagulants (NOACs), and their educational needs: A qualitative study. <i>Thrombosis Research</i> , 2017 , 153, 19-27	8.2	25
209	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). <i>Europace</i> , 2017 , 19, 190-225	3.9 5	44
208	Pre-participation cardiovascular evaluation for athletic participants to prevent sudden death: Position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. <i>Europace</i> , 2017 , 19, 139-163	3.9	36
207	Self-reported physical activity and major adverse events in patients with atrial fibrillation: a report from the EURObservational Research Programme Pilot Survey on Atrial Fibrillation (EORP-AF) General Registry. <i>Europace</i> , 2017 , 19, 535-543	3.9	26
206	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017 , 38, 852-859	9.5	50
205	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017 , 38, 860-868	9.5	75
204	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , 2017 , 130, 1388-1396	. <u>ê</u> ∙ 6	110
203	Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. <i>American Journal of Cardiology</i> , 2017 , 120, 1139-1145	3	32
202	Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. <i>Heart Failure Reviews</i> , 2017 , 22, 731-741	5	60

201	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 1203-1213	6.4	28
200	Secondary Versus Primary Stroke Prevention in Atrial Fibrillation: Insights From the Darlington Atrial Fibrillation Registry. <i>Stroke</i> , 2017 , 48, 2198-2205	6.7	17
199	European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). European Journal of	3.9	43
198	European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacili Cardiaca y Electrofisiologia	3.9	85
197	Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de	3.9	137
196	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacili Cardlica y Electrofisiologii (SOLAECE). <i>Europace</i> , 2017 ,	3.9	135
195	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart	3.9	75
194	Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation. European Heart Journal, 2017 , 38, 2980-298217, 19, 1757-1758	9.5	9
193	Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 209-218	7	124
192	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working	7	29
191	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2016 , 18, 12-36	3.9	37
190	Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. <i>Age and Ageing</i> , 2016 , 45, 767-775	3	44
189	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	14
188	Atrial fibrillation. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16016	51.1	115
187	ACP Journal Club. The 5-factor ORBIT bleeding score predicted major bleeding at 2 years in patients with atrial fibrillation. <i>Annals of Internal Medicine</i> , 2016 , 164, JC11	8	2
186	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <i>EBioMedicine</i> , 2016 , 8, 309-316	8.8	28
185	Relation of Nonvalvular Atrial Fibrillation to Body Mass Index (from the SPORTIF Trials). <i>American Journal of Cardiology</i> , 2016 , 118, 72-8	3	21
184	Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes. <i>International Journal of Cardiology</i> , 2016 , 203, 660-6	3.2	116

(2015-2016)

183	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016 , 18, 37-50	3.9	90	
182	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. <i>American Journal of Medicine</i> , 2016 , 129, 600-7	2.4	75	
181	PatientsPand physiciansPexperiences of atrial fibrillation consultations and anticoagulation decision-making: A multi-perspective IPA design. <i>Psychology and Health</i> , 2016 , 31, 436-55	2.9	31	
180	Patient-Reported Outcomes for Quality of Life Assessment in Atrial Fibrillation: A Systematic Review of Measurement Properties. <i>PLoS ONE</i> , 2016 , 11, e0165790	3.7	28	
179	Non-Vitamin K Oral Anticoagulant Drugs for Stroke Prevention in Patients with Atrial Fibrillation and Chronic Kidney Disease. <i>Current Medicinal Chemistry</i> , 2016 , 23, 2055-69	4.3	2	
178	A bifactor model of the Beck Depression Inventory and its association with medical prognosis after myocardial infarction. <i>Health Psychology</i> , 2016 , 35, 614-24	5	13	
177	Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Establacia Cardiaca	3.2	3	
176	y Electrofisiologia (SOLAECE). Arrhythmia and Electrophysiology Review, 2016 , 5, 210-224 Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. <i>Healthcare (Switzerland)</i> , 2016 , 4,	3.4	5	
175	Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 1711-4	15.4	77	
174	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , 2016 , 102, 1878-1882	5.1	15	
173	AdolescentsPand Young AdultsPLived Experiences Following Venous Thromboembolism: "It will always lie in wait". <i>Nursing Research</i> , 2016 , 65, 455-464	1.9	13	
172	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. <i>Scientific Reports</i> , 2016 , 6, 24376	4.9	40	
171	Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials. <i>International Journal of Cardiology</i> , 2016 , 216, 168-72	3.2	14	
170	Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. <i>Circulation</i> , 2015 , 131, e412-5	16.7	10	
169	Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial Fibrillation: AMADEUS Trial. <i>Stroke</i> , 2015 , 46, 2523-8	6.7	43	
168	Impact of advanced age on management and prognosis in atrial fibrillation: insights from a population-based study in general practice. <i>Age and Ageing</i> , 2015 , 44, 874-8	3	51	
167	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart	3.9	89	
166	Rhythm Society. <i>Europace</i> , 2015 , 17, 1169-96 Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study. <i>Stroke</i> , 2015 , 46, 2168-74	6.7	56	

165	Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort study. <i>Thrombosis Research</i> , 2015 , 135, 643-7	8.2	11
164	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015 , 104, 418-29	6.1	77
163	Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 1155-63	2.5	1
162	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of	3.9	426
161	Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 1030-8	27.4	192
160	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015 , 17, 1467-507	3.9	803
159	Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2015 , 201, 195-9	3.2	5
158	Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. <i>BMJ, The</i> , 2015 , 351, h4451	5.9	172
157	Assessing Eligibility for Anticoagulation After Diagnosis of Atrial FibrillationReply. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 949-50	27.4	1
156	Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population: A modeling analysis. <i>International Journal of Cardiology</i> , 2015 , 181, 247-54	3.2	5
155	Net clinical benefit of edoxaban versus no treatment in a Real worldPatrial fibrillation population: A modelling analysis based on a nationwide cohort study. <i>International Journal of Cardiology</i> , 2015 , 201, 693-8	3.2	13
154	Optimising stroke prevention in patients with atrial fibrillation. <i>British Journal of General Practice</i> , 2015 , 65, 117	1.6	3
153	Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation Imeta-analysis. <i>Circulation Journal</i> , 2015 , 79, 339-45	2.9	30
152	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. <i>British Journal of General Practice</i> , 2015 , 65, e16-23	1.6	31
151	Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic. <i>International Journal of Clinical Practice</i> , 2015 , 69, 1341-8	2.9	13
150	Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. <i>European Journal of Heart Failure</i> , 2015 , 17, 1192-200	12.3	82
149	Stroke prevention in atrial fibrillation: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1950-62	27.4	187
148	Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. <i>International Journal of Clinical Practice</i> , 2015 , 69, 840-5	2.9	17

(2014-2015)

147	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci	3.9	94
146	Cardlica y Electrofisiologii (SOLEACE). Europace, 2015 , 17, 1747-69 Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. Journal of Thrombosis and Haemostasis, 2015 , 13, 495-504	15.4	110
145	Atrial fibrillation (chronic). Clinical Evidence, 2015, 2015,		1
144	Best practice for atrial fibrillation patient education. <i>Current Pharmaceutical Design</i> , 2015 , 21, 533-43	3.3	45
143	Myocardial ischemic events in Peal worldPpatients with atrial fibrillation treated with dabigatran or warfarin. <i>American Journal of Medicine</i> , 2014 , 127, 329-336.e4	2.4	56
142	The reply. American Journal of Medicine, 2014 , 127, e21	2.4	
141	Oral anticoagulants for stroke prevention in atrial fibrillation. <i>Current Problems in Cardiology</i> , 2014 , 39, 319-44	17.1	4
140	The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. <i>Clinical Therapeutics</i> , 2014 , 36, 1135-44	3.5	42
139	Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. <i>American Journal of Medicine</i> , 2014 , 127, 1172-8.e5	2.4	36
138	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis,	9.5	413
137	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014 , 16, 1655-73	3.9	77
136	Atrial fibrillation and heart failure: a bad combination. <i>American Journal of Cardiology</i> , 2014 , 113, 1196-7	73	9
135	Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2-VASc, R2 CHADS2, HAS-BLED, ATRIA, and more). <i>Clinical Cardiology</i> , 2014 , 37, 634	1-3434	35
134	The impact of smoking on thromboembolism and mortality in patients with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health study. <i>Chest</i> , 2014 , 145, 559-66	5.3	40
133	The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide cohort study. <i>Chest</i> , 2014 , 146, 1337-1346	5.3	29
132	Stroke and bleeding risk in atrial fibrillation. <i>Korean Circulation Journal</i> , 2014 , 44, 281-90	2.2	29
131	Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation. The prospective Danish Diet, Cancer and Health study. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 789-95	7	10
130	Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014 , 107, 955-67	2.7	97

129	Use of the HAS-BLED bleeding score in real-life settings. <i>Thrombosis Research</i> , 2014 , 134, 202	8.2	2
128	An evaluation of the Minnesota Living with Heart Failure Questionnaire using Rasch analysis. <i>Quality of Life Research</i> , 2014 , 23, 1753-65	3.7	16
127	Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. <i>Journal of Human Hypertension</i> , 2013 , 27, 72-8	2.6	27
126	Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. <i>Netherlands Heart Journal</i> , 2013 , 21, 354-63	2.2	23
125	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013 , 15, 1540-56	3.9	101
124	Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2013 , 167, 2682-7	3.2	55
123	Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 386-7	15.1	59
122	Reply: To PMID 22858389. Journal of the American College of Cardiology, 2013, 61, 482-483	15.1	
121	Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE registry. <i>International Journal of Cardiology</i> , 2013 , 168, 1644-6	3.2	13
120	Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. <i>Canadian Journal of Cardiology</i> , 2013 , 29, S4-S13	3.8	23
119	Treatment of hypertension in peripheral arterial disease. <i>The Cochrane Library</i> , 2013 , CD003075	5.2	20
118	Letter by Apostolakis et al regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With	16.7	5
117	Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. <i>British Journal of Psychiatry</i> , 2013 , 203, 90-	1 5∕2	128
116	Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013 , 106, 795-802	2.7	56
115	Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. <i>European Heart Journal</i> , 2013 , 34, 3572-9	9.5	66
114	The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 975-87	15.4	34
113	Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 77-90	2.5	7
112	Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future cardiovascular events in a Real-worldPcommunity cohort of patients with atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 1032-8	4.6	28

111	Alcohol intake and prognosis of atrial fibrillation. <i>Heart</i> , 2013 , 99, 1093-9	5.1	45
110	Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project. <i>Hypertension Research</i> , 2013 , 36, 546-9	4.7	2
109	Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillationfocus on the elderly. <i>Circulation Journal</i> , 2013 , 77, 1380-8	2.9	31
108	Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1074-9	7	80
107	Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 328-36	7	43
106	Psychological interventions for depression in adolescent and adult congenital heart disease. <i>The Cochrane Library</i> , 2013 , CD004372	5.2	19
105	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <i>Cochrane Database of Systematic Reviews</i> , 2013 , CD008600		34
104	Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study. <i>Chest</i> , 2013 , 144, 1839-1847	5.3	27
103	Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. <i>PLoS ONE</i> , 2013 , 8, e74037	3.7	131
102	Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. <i>Health Technology Assessment</i> , 2013 , 17, 1-188	4.4	22
101	Hemorrhage Risks, Patient Perspectives, and Quality-of-Life Issues 2013 , 41-51		
100	Stroke and thromboembolism in atrial fibrillation. Circulation Journal, 2012, 76, 2289-304	2.9	100
99	Atrial fibrillation. Lancet, The, 2012, 379, 648-61	40	287
98	To the Editor - Adding renal dysfunction to CHADSEVASc improves stroke prediction postcatheter ablation. <i>Heart Rhythm</i> , 2012 , 9, e25; author reply e26	6.7	
97	Stroke and bleeding in atrial fibrillation with chronic kidney disease. <i>New England Journal of Medicine</i> , 2012 , 367, 625-35	59.2	624
96	PatientsPand health professionalsPviews and experiences of atrial fibrillation and oral-anticoagulant therapy: a qualitative meta-synthesis. <i>Patient Education and Counseling</i> , 2012 , 88, 330-7	3.1	42
95	The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. <i>Chest</i> , 2012 , 142, 1489-1498	5.3	281
94	The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 194-5; author reply 195	15.1	14

93	Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. <i>Journal</i>	15.1	265
92	of the American College of Cardiology, 2012 , 60, 861-7 Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. <i>American Journal of Medicine</i> , 2012 , 125, 826.e13-23	2.4	62
91	Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. <i>Circulation</i> , 2012 , 126, 860-5	16.7	259
90	RCPE UK Consensus Conference on Papproaching the comprehensive management of atrial fibrillation: evolution or revolution? P. Journal of the Royal College of Physicians of Edinburgh, The, 2012, 42, 34-5	0.9	17
89	Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a Real worldPatrial fibrillation population: a modelling analysis based on a nationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 584-9	7	239
88	Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e531S-e575S	5.3	763
87	Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 941-8	6.4	58
86	Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012 , 14, 681-95	12.3	57
85	Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. <i>European Journal of Heart Failure</i> , 2012 , 14, 295-301	12.3	81
84	Angiogenin and hemoxygenase in pregnancy: influence of hypertension. <i>Angiology</i> , 2012 , 63, 194-8	2.1	8
83	Soluble Fas and Fas ligand in pregnancy: influence of hypertension. <i>Angiology</i> , 2012 , 63, 35-8	2.1	7
82	Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic optionsa report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2012 , 14, 8-27	3.9	156
81	Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. <i>Chest</i> , 2012 , 141, 147-153	5.3	82
80	Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study. <i>Journal of Hypertension</i> , 2012 , 30, 974-9	1.9	6
79	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1009-22	7	49
78	Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. <i>Journal</i>	15.1	721
77	Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1339-48	15.1	156
76	Comparative Analysis of the HAS-BLED Score With Other Bleeding Risk Scores, Using Estimates of Net Reclassification Improvement and Integrated Discrimination Improvement. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1398-1399	15.1	3

75	Bleeding risk in patients with atrial fibrillation: the AMADEUS study. <i>Chest</i> , 2011 , 140, 146-155	5.3	20
74	Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a Preal worldPnationwide cohort study. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 739-49	7	332
73	Angiogenin and apoptosis in hypertension in pregnancy. <i>Pregnancy Hypertension</i> , 2011 , 1, 191-6	2.6	5
72	The quest for new anticoagulants: from clinical development to clinical practice. <i>Cardiovascular Therapeutics</i> , 2011 , 29, e12-22	3.3	8
71	Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 1012-9	7	60
70	Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. <i>Thrombosis and Haemostasis</i> ,	7	184
69	Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in pregnancy: a report of ninety-one pregnancies. <i>Journal of Hypertension</i> , 2011 , 29, 396-9	1.9	27
68	Assessing the Performance of the HAS-BLED Score: Response. <i>Chest</i> , 2011 , 139, 1248	5.3	
67	A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 39-48	15.4	193
66	Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population. <i>Journal of Cardiovascular Electrophysiology</i> , 2011 , 22, 25-30	2.7	56
65	Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. <i>Clinical Research in Cardiology</i> , 2011 , 100, 531-7	6.1	23
64	The HAS-BLED Score and Renal Failure: Response. <i>Chest</i> , 2011 , 139, 1249-1250	5.3	2
63	Can we IMPROVE bleeding risk assessment for acutely ill, hospitalized medical patients?. <i>Chest</i> , 2011 , 139, 10-3	5.3	19
62	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011 , 13, 723-46	3.9	166
61	Short-term effects of screening for cardiovascular risk in the deaf community: a pilot study. <i>Cardiology Research and Practice</i> , 2011 , 2011, 493546	1.9	4
60	Atrial fibrillation (chronic). <i>Clinical Evidence</i> , 2011 , 2011,		1
59	Anticoagulation for atrial fibrillation patients with CHADS score of 1. <i>Journal of Cardiovascular Electrophysiology</i> , 2010 , 21, 508-10	2.7	5
58	Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 122-7	7	58

57	Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2-VASc risk stratification scores. <i>Age and Ageing</i> , 2010 , 39, 533-5	3	36
56	The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 1703-10	2.5	2
55	Atrial fibrillation and mortality: the impact of antithrombotic therapy. <i>European Heart Journal</i> , 2010 , 31, 2075-6	9.5	5
54	Impact of symptom control on health-related quality of life in atrial fibrillation patients: the psychologistB viewpoint. <i>Europace</i> , 2010 , 12, 608-10	3.9	9
53	Obstructive Sleep Apnea Is a Risk Factor for Stroke and Atrial Fibrillation: Response. <i>Chest</i> , 2010 , 138, 239-240	5.3	4
52	CHA 2 DS 2 -VASc Risk Scheme: Response. <i>Chest</i> , 2010 , 138, 1020-1021	5.3	2
51	Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. <i>Stroke</i> , 2010 , 41, 2731-8	6.7	368
50	Stroke prevention in atrial fibrillation patients. Expert Opinion on Pharmacotherapy, 2010, 11, 2331-50	4	4
49	Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 827-37	15.1	168
48	Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?. <i>American Journal of Medicine</i> , 2010 , 123, 785-9	2.4	92
47	A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. <i>Chest</i> , 2010 , 138, 1093-100	5.3	2947
46	Quality of anticoagulation control in atrial fibrillation. <i>Lancet, The</i> , 2010 , 376, 935-7	40	3
45	Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. <i>Chest</i> , 2010 , 137, 263-72	5.3	4353
44	Advances in therapy for atrial fibrillation. <i>Therapy: Open Access in Clinical Medicine</i> , 2010 , 7, 103-105		
43	Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk. <i>Lancet Neurology, The</i> , 2010 , 9, 1140-1142	24.1	8
42	TRial of an Educational intervention on patientsPknowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT). <i>BMC Cardiovascular Disorders</i> , 2010 , 10, 21	2.3	25
41	Haemorrhage risks, patient perspectives, and quality-of-life issues 2010 , 35-42		
40	Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation". <i>Thrombosis and Haemostasis</i> , 2009 , 102, 914-5	7	11

(2007-2009)

39	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 802-805	7	62
38	Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand factor and circulating endothelial cells, following acute myocardial infarction. <i>Annals of Medicine</i> , 2009 , 41, 608-18	1.5	6
37	Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves. <i>Chest</i> , 2009 , 136, 1451-1452	5.3	1
36	Quality of life in older people with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2009 , 25, 37-42	2.4	30
35	Improving survival of malignant hypertension patients over 40 years. <i>American Journal of Hypertension</i> , 2009 , 22, 1199-204	2.3	67
34	Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. <i>Journal of Psychosomatic Research</i> , 2009 , 66, 203-10	4.1	75
33	Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and literature review. <i>American Journal of Medicine</i> , 2009 , 122, 851-856.e3	2.4	30
32	Treatment of hypertension in peripheral arterial disease. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD003075		7
31	Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial fibrillation. <i>Blood Coagulation and Fibrinolysis</i> , 2009 , 20, 392-3	1	5
30	Challenges facing anticoagulation among the elderly and frail. <i>Age and Ageing</i> , 2009 , 38, 140-2	3	6
29	Atrial fibrillation and stroke risk prevention in real-life clinical practice. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 415-416	7	5
28	Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 802-5	7	15
27	Vital exhaustion and cardiovascular disease: are circulating fibrinogen and D-dimer levels a plausible link?. <i>Stress</i> , 2008 , 11, 247-9	3	2
26	Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors. <i>Stroke</i> , 2008 , 39, 7-9	6.7	40
25	Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin?. <i>Thrombosis and Haemostasis</i> , 2008 , 100, 955-957	7	22
24	Cross-cultural adaptation into Punjabi of the English version of the Hospital Anxiety and Depression Scale. <i>BMC Psychiatry</i> , 2007 , 7, 5	4.2	8
23	Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a multidrug regime including an angiotensin-blocking agent. <i>Journal of Hypertension</i> , 2007 , 25, 2515-	·6 ^{1.9}	17
22	Low-dose spironolactone in the management of resistant hypertension: a surveillance study. <i>Journal of Hypertension</i> , 2007 , 25, 891-4	1.9	96

21	Depression, anxiety, and quality of life in patients with atrial fibrillation. <i>Chest</i> , 2007 , 132, 1259-64	5.3	182
20	Maintaining therapeutic anticoagulation: the importance of keeping "within range". <i>Chest</i> , 2007 , 131, 1277-9	5.3	15
19	Circulating endothelial cells, arterial stiffness, and cardiovascular risk stratification in hypertension. <i>Chest</i> , 2007 , 132, 1540-7	5.3	25
18	A systematic review of the effects of acute psychological stress and physical activity on haemorheology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of acute coronary syndromes. <i>Thrombosis Research</i> , 2007 , 120, 819-47	8.2	97
17	Quality of life in patients with atrial fibrillation: a systematic review. <i>American Journal of Medicine</i> , 2006 , 119, 448.e1-19	2.4	372
16	Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. <i>International Journal of Cardiology</i> , 2006 , 110, 354-8	3.2	124
15	Bleeding risk stratification models in deciding on anticoagulation in patients with atrial fibrillation: a useful complement to stroke risk stratification schema. <i>Chest</i> , 2006 , 130, 1296-9	5.3	17
14	Anticoagulation control with vitamin K antagonists: how well are we doing?. <i>Chest</i> , 2006 , 129, 1122-4	5.3	3
13	Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. <i>Stroke</i> , 2006 , 37, 2294-300	6.7	119
12	Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed venous blood. <i>Journal of Thrombosis and Thrombolysis</i> , 2006 , 22, 125-31	5.1	13
11	Psychological interventions for depression in heart failure. <i>The Cochrane Library</i> , 2005 , CD003329	5.2	28
10	Recruitment of ethnic minority patients to a cardiac rehabilitation trial: the Birmingham Rehabilitation Uptake Maximisation (BRUM) study [ISRCTN72884263]. <i>BMC Medical Research Methodology</i> , 2005 , 5, 18	4.7	22
9	Anti-thrombotic therapy for atrial fibrillation and patientsPpreferences for treatment. <i>Age and Ageing</i> , 2005 , 34, 1-3	3	14
8	Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study (BRUM): a randomised controlled trial [ISRCTN72884263]. BMC Cardiovascular Disorders,	2.3	35
7	Psychological interventions for depression in adolescent and adult congenital heart disease 2003 ,		4
6	The prevalence and persistence of depression and anxiety following myocardial infarction. <i>British Journal of Health Psychology</i> , 2002 , 7, 11-21	8.3	124
5	In-hospital symptoms of depression do not predict mortality 3 years after myocardial infarction. <i>International Journal of Epidemiology</i> , 2002 , 31, 1179-82	7.8	56
4	Predictors of attendance at cardiac rehabilitation after myocardial infarction. <i>Journal of Psychosomatic Research</i> , 2001 , 51, 497-501	4.1	131

LIST OF PUBLICATIONS

3	Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. <i>Psychosomatic Medicine</i> , 2001 , 63, 221-30	3.7	282
2	Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2000 , 93, 739-44	2.7	44
1	Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. <i>Journal of Psychosomatic Research</i> , 2000 , 49, 229-38	4.1	126